Stockscreener 앱 받기
41.83
6.28%
2.47
Moderna Inc 주식(MRNA)의 최신 뉴스
Moderna Shares Surge Amid Positive Earnings and Regulatory News - StocksToTrade
Moderna’s Market Gains as Revenue Projections Boost Investor Confidence - timothysykes.com
Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA - TechStock²
OVERSEA CHINESE BANKING Corp Ltd Sells 37,172 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna (NASDAQ:MRNA) Upgraded at Wall Street Zen - MarketBeat
Moderna Stock vs Competition: Who Wins? - Trefis
Weekly Market Update: Stocks Remain Flat as Consumer Defensives Rise and Financial Services Fall - morningstar.com
I Hope Moderna (MRNA) Posts Growth, Says Jim Cramer - Finviz
Moderna (NASDAQ:MRNA) Shares Gap UpStill a Buy? - MarketBeat
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026 - FinancialContent
Arbutus falls as patent dispute with Moderna hits EU snag - Seeking Alpha
Moderna's Q4 2025 Earnings: What to Expect - Barchart.com
Best Biotech Stocks To Keep An Eye OnJanuary 15th - MarketBeat
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz
Analysts Set Expectations for Moderna FY2030 Earnings - MarketBeat
Non-covid mRNA Vaccine and Therapeutics Market Exclusive Report on the Latest Revenue and Future Scope - openPR.com
Aug Drivers: Is Moderna Inc a turnaround story2025 Trading Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Moderna projects 10% growth next year; lifts outlook for year-end liquidity - MSN
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot - FinancialContent
Moderna (MRNA) Stock: Biotech Leader Surges 30% on Updated Guidance - Blockonomi
Moderna (MRNA) rockets 17% on strong preliminary FY25 results - MSN
Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results - Insider Monkey
Moderna Inc.: From Pandemic Phenomenon to mRNA Platform Powerhouse - AD HOC NEWS
Building Companies Like Experiments: The Flagship Pioneering Model - Citeline News & Insights
Trending tickers: Nvidia, Intel, Moderna, BP and Vistry - Yahoo Finance UK
Moderna (MRNA) Stock: Biotech Breaks Out With 30% Rally in 2026 - CoinCentral
Moderna 2026 at JPM 2026: Projects $1.9B Revenue and Eyes Vaccine Approvals - geneonline.com
Intel, Moderna, Adobe, BitMine Immersion And Strategy: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target - BioPharma Dive
Moderna Eyes Higher Revenue and Strategic Approvals at J.P. Morgan Event - timothysykes.com
Adobe stock downgraded, Moderna surges on upbeat guidance - Yahoo Finance
Moderna (NASDAQ:MRNA) Shares Up 7.1%Still a Buy? - MarketBeat
Moderna rallies after projecting better-than-expected 2025 sales - Sherwood News
Why Moderna Stock Strength Is Only Beginning: Technical Analysis - Barron's
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
Moderna (MRNA) Shares Surge by Nearly 13% - GuruFocus
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday - Benzinga
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next - TechStock²
Moderna jumps 12% after 2025 projections - breakingthenews.net
Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story (MRNA) - Seeking Alpha
Moderna updates 2025 outlook and highlights pipeline progress - The Globe and Mail
Moderna says possible allergic reactions to Covid-19 vaccine under investigation - The Daily Star
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - The Providence Journal
Moderna chair says US assault on science is just beginning - The Daily Gazette
Commonwealth Fusion Systems Appoints Stephane Bancel, Moderna CEO, to Its Board of Directors - energynews
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape - FinancialContent
Moderna Chair Says US Assault on Science Is Just Beginning - Bloomberg.com
Commonwealth Fusion Systems Appoints Stephane Bancel To Board - citybiz
Moderna expects 2025 revenue of $1.9B, above guidance - Proactive financial news
Aug Decliners: Should you avoid Moderna Inc stock right now2025 Biggest Moves & High Win Rate Trade Alerts - baoquankhu1.vn
Goldman Sachs Adjusts Price Target on Moderna to $36 From $33, Maintains Neutral Rating - marketscreener.com
Why Moderna Stock Is Dropping After Good News - Barron's
Moderna Sees 2025 Revenue Close to Outlook Range, Affirms Growth Target For This Year - marketscreener.com
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast - BioSpace
Moderna says its expects $1.9 billion in 2025 sales amid better-than-expected vaccination rate - Sherwood News
Moderna raises its forecasts and the stock rises before the opening of the US market - المتداول العربي
Moderna sees sales boost as COVID shots beat expectations - The Detroit News
Market movers: Synchrony Financial, Capital One, NextSource Materials, Moderna... - Proactive financial news
Moderna (MRNA) Projects Up to 10% Revenue Growth by 2026 - GuruFocus
Moderna stock rises. Revenue in 2025 will be higher than midpoint of guidance - MSN
Moderna updates on business and pipeline at JPM conference - The Pharma Letter
Moderna Stock Rises. Revenue in 2025 Will Be Higher Than Midpoint of Guidance. - Barron's
Moderna reiterates target of up to 10% revenue growth in 2026 (MRNA:NASDAQ) - Seeking Alpha
Commonwealth Fusion Systems Names Stephane Bancel to Board of Directors - PR Newswire
Moderna expects $1.9 billion revenue for 2025, exceeds cost targets - Investing.com
Moderna expects sales near upper end of 2025 forecast - Business Day
4.73%
0.92%
자본화:
|
볼륨(24시간):